Welcome to our dedicated page for AIKI news (Ticker: aiki), a resource for investors and traders seeking the latest updates and insights on AIKI stock.
AIkido Pharma Inc. (AIKI), a biotechnology innovator since 1967, develops targeted cancer treatments and broad-spectrum antiviral therapies through academic collaborations. This page aggregates official announcements and analysis-worthy developments for stakeholders tracking the company's progress.
Access timely updates on clinical milestones, strategic partnerships with leading research institutions, and corporate initiatives like the active share repurchase program. Key focus areas include pancreatic cancer therapies, leukemia treatments, and novel antiviral platforms addressing multiple infectious diseases.
Regularly updated content covers licensing agreements, preclinical results, financial disclosures, and market expansion efforts. Bookmark this page to efficiently monitor AIkido Pharma's evolving role in oncology and virology research without navigating multiple sources.
AIkido Pharma Inc. (Nasdaq: AIKI) announced enhancements in the manufacturing process for its pancreatic cancer treatment, DHA-dFdC. The Company has developed a new production method that allows for scaled production of a key intermediate compound, aiming to lower costs and increase output. Additionally, AIkido was issued U.S. Patent No. 11,219,633, extending protection for the drug until May 2035, and has filed a continuation patent application for further protection. CEO Anthony Hayes expressed optimism about the advancements and their potential impact on drug development.
AIkido Pharma Inc. (Nasdaq: AIKI) has closed a registered direct offering of 11,000 shares each of Series O and Series P redeemable convertible preferred stock, raising approximately $20.9 million. Priced at $952.38 per share, this offering includes an original issue discount of 5%. The preferred stocks can convert into common stock at an initial price of $1.00 per share, contingent on stockholder approval for a reverse stock split. Net proceeds will be used for working capital and general corporate purposes.
AIkido Pharma (Nasdaq: AIKI) has entered a securities purchase agreement to sell 11,000 shares each of Series O and P redeemable convertible preferred stock at $952.38 per share, totaling approximately $20.9 million in net proceeds. These shares are convertible into common stock at $1.00 per share, contingent on shareholder approval for a reverse stock split. The Series P shares grant significant voting power on this proposal. The offering is facilitated by H.C. Wainwright & Co., with proceeds intended for working capital and corporate purposes.
AIkido Pharma Inc. (NASDAQ: AIKI) announced a share repurchase program, authorizing the buyback of up to $3 million of its common stock, effective immediately. This decision underscores the Company's commitment to shareholder value and reflects a strong balance sheet. CEO Anthony Hayes stated that the program aligns with the Company's growth strategies and anticipates multiple monetization events in 2022 to enhance shareholder value further.
AIkido Pharma Inc. (Nasdaq: AIKI) announced Dr. Rachel Yehuda's appearance on CBS News discussing a recent FDA-approved trial involving a psychedelic drug aimed at treating PTSD. The segment highlights a former Marine's struggles with PTSD and his newfound hope through this research. AIkido expresses support for Dr. Yehuda's work and emphasizes its commitment to veterans. The company, founded in 1967, is also involved in developing anti-cancer therapeutics and a broad-spectrum antiviral platform targeting multiple viruses.
AIkido Pharma Inc. (Nasdaq: AIKI) has announced plans to expand its patent applications for its pancreatic cancer drug and antiviral treatments into key international markets, including China, India, and all member countries of the European Patent Office. The company's CEO, Anthony Hayes, emphasized the importance of solid patent protection for future market share. This strategic move is a step towards enhancing the company’s footprint in the global healthcare market.
AIkido Pharma (Nasdaq: AIKI) announced a strategic equity interest in ASP Isotopes, focusing on non-nuclear enriched isotopes, on December 6, 2021. The investment aims to solve supply chain issues for Technetium-99m, derived from molybdenum-100. ASP Isotopes is constructing a 20 Kg/year production plant in South Africa, with high demand from customers. By 2028, they project generating over $150 million in EBITDA. AIkido's CEO highlighted the opportunity for potential monetization in early 2022 amidst a $3.8 billion Mo-99 market. The move aligns with AIkido's strategy to enhance shareholder value.
AIkido Pharma Inc. (Nasdaq: AIKI) reported its Q3 2021 financial highlights, revealing cash and investments over $104 million with low cash burn. A key achievement was a liquidity event in DatChat, yielding over 600% ROI. The company diversified its investment portfolio, including stakes in Tevva Motors, Kerna Health, Slinger Bag, and Kaya Holdings, targeting high-growth sectors. AIkido is actively advancing its drug platform through partnerships with top universities to develop antiviral therapies. Despite a strong balance sheet, the CEO emphasized that the company's valuation does not reflect its asset value.
AIkido Pharma Inc. (AIKI) announced its equity interest in Tevva Motors Ltd, an electric truck manufacturer. Tevva specializes in modular electrification systems for medium-duty vehicles, tapping into a $100 billion global delivery truck market. CEO Anthony Hayes emphasized the growing demand for cost-effective, zero-emission solutions, with Tevva's technology already in use by partners like UPS and Hitachi. AIkido sees potential for shareholder value through Tevva's upcoming public listing. The company continues to focus on drug development while exploring high-growth opportunities.
